Rifapentine is active in vitro and in vivo against Toxoplasma gondii

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 6, 1996, Pages 1335-1337

  Araujo, Fausto G ^a   Khan, Anis A ^a   Remington, Jack S ^a,b  

^a PALO ALTO MEDICAL FOUNDATION   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; ATOVAQUONE; RIFABUTIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DEATH; DOSE RESPONSE; FEMALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 0030028511     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.6.1335     Document Type: Article

References (16)

1. Alessandro, A., B. Ratti, and T. Cristina. 1984. Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse, and the rabbit. J. Antibiot. 37:1066-1075
2. Araujo, F. G., J. Huskinson, and J. S. Remington. 1991. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii Antimicrob. Agents Chemother. 35:293-299
3. Araujo, F. G., and J. S. Remington. 1992. Recent advances in the search for new drugs for treatment of toxoplasmosis. Int. J. Antimicrob. Agents 1:153-164.
4. Araujo, F. G., T. Slifer, and J. S. Remington. 1994. Rifabutin is active in models of murine toxoplasmosis Antimicrob. Agents Chemother. 38:570-575.
5. Brown, S. T., F. F. Edwards, E. M. Bernard, W. Tong, and D. Armstrong. 1993. Azythromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine Antimicrob. Agents Chemother. 37:398-402.
6. Chan, S. L., W. W. Yew, J. H. D. Porter, K. P. W. G. McAdam, B. W. Allen, J. M. Dickinson, G. A. Ellard, and D. A. Michison. 1994. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J. Antimicrob. Agents 3:267-274.
7. Chapuis, L., B. Ji, C. Trullot-Pernot, R. J. O'Brien, M. C. Raviglione, and J. H. Grosset. 1994. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am. J. Respir. Crit. Care Med 150:1355-1362.
8. Israelski, D. M., and J. S. Remington. 1988. Toxoplasmic encephalitis in patients with AIDS. Infect. Dis. Clin N. Am. 2:429-445
9. Klemens, S. P., and M. H. Cynamon. 1992. Activity of rifapentine against Mycobacterium avium infection in beige mice J. Antimicrob. Chemother. 29: 555-561.
10. Klemens, S. P., M. A. Grossi, and M. H. Cynamon. 1994. Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex. Antimicrob Agents Chemother. 38:234-237.
11. Laughon, B. E., H. S. Allaudeen, J. M. Becker, W. L. Current, J. Feinberg, J. K. Frenkel, R. Hafner, W. T. Hughes, C. Laughlin, J. Meyers, L. K. Schrager, and L. S. Young. 1991. Summary of the Workshop on Future Directions in Discovery and Development of Therapeutic Agents for Opportunistic Infections Associated with AIDS. J Infect. Dis. 164:244-251
12. Luft, B. J., R. Hafner, A. Korzun, C. Leport, D. Antoniskis, E. Bosler, and D. Burland. 1993. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome N. Engl. J. Med. 329:995-1000.
13. Mitchison, D. A., G. A. Ellard, and J. Grosset. 1988. New antibacterial drugs for the treatment of mycobacterial disease in man. Br. Med Bull. 44:757-774.
14. Mosman, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63.
15. Wong, S. Y., D. M. Israelski, and J. S. Remington. 1995. AIDS associated toxoplasmosis, 4th ed M. A. Sande and P Volberding (coordinating ed.) The W. B Saunders Co., Philadelphia
16. Wong, S. Y., and J. S. Remington. 1994. Toxoplasmosis in the setting of AIDS. S. Broder, T. C Merigan, and D Bolognesi (coordinating ed). The Williams & Wilkins Co., Baltimore